Can AbbVie (ABBV) Still Be A Bargain After Trial Wins?

AbbVie stock has delivered a powerful run over the past few years, so the obvious question now is whether today's US$285.64 price still lines up with the cash the business is expected to generate. With investors focused on new therapies across immunology and oncology, the debate is shifting to what AbbVie’s cash flows really justify.

• Over the past 5 years AbbVie has returned 197.5% which puts a lot of expectation into what its future cash flows can support.
• Recent positive trial results for drugs like lutikizumab and ABBV-466 may support assumptions for longer lasting and potentially expanding cash flows if these therapies convert into commercial franchises.
• Prefer to judge AbbVie on earnings? See why AbbVie's 80.5x P/E tells a different valuation story.

The issue now is whether AbbVie’s current share price is appropriately anchored to the intrinsic value implied by its cash flows.

If you want to test the same cash flow question across a wider field than AbbVie, scan a basket of 29 high quality undervalued stocks and compare how their current prices stack up against projected fundamentals.

Is AbbVie Still Cheap on Cash Flow?

The Discounted Cash Flow (DCF) model here focuses on AbbVie’s ability to turn its drug portfolio into future cash for shareholders. Over the latest twelve months the group generated roughly $18.3b of free cash flow, and the projections assume those cash flows continue growing rather than shrinking, with analysts expecting higher annual free cash flow by 2030 based on both current franchises and a maturing pipeline.

Those assumptions feed into a two stage Free Cash Flow to Equity framework. This points to an intrinsic value that the model suggests is substantially above the current $285.64 share price. The strong Phase 3 INTREPID data for lutikizumab in hidradenitis suppurativa gives some support to the idea that AbbVie can sustain meaningful cash generation beyond its existing blockbusters, because the market is still pricing the stock below what its cash flows support. Find out what AbbVie could be worth using our Discounted Cash Flow (DCF) estimate.

The AbbVie Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the AbbVie valuation question leaves off. Each one translates that gap between price and cash flow into a clear set of future assumptions for AbbVie’s growth, margins and earnings that would need to hold for the shares to be worth materially more or less than today’s level. Rather than relying on a single multiple or model line, they lay out the key inputs behind each fair value so you can compare those expectations with actual results over time. They sit on Simply Wall St’s Community page and are intended as a reference point alongside your own work.

One of the top community narratives on AbbVie: roughly fairly valued

"The key requirement for AbbVie is successfully executing on its pipeline and business development so that new immunology, oncology and neuroscience drugs replace revenue from declining products such as Humira and Imbruvica..."

Discover why this Narrative puts AbbVie at roughly fairly valued.

AbbVie’s valuation still leaves one critical issue on the table

AbbVie’s pricing and cash flow story is only half of what matters, because internal checks have also flagged potential pressure points that deserve your attention before drawing any firm view. Take a closer look at 4 warning signs before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com